Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
Epithalon (Injectable Form)
Epitalon Injectable, AEDG Injectable
The injectable subcutaneous form of the Epithalon tetrapeptide, offering higher bioavailability than oral or nasal routes. Same active sequence (Ala-Glu-Asp-Gly) as oral Epitalon but delivered via injection for more reliable absorption. Studied for telomerase activation, pineal gland function, and circadian rhythm regulation.
A synthetic tetrapeptide (Ala-Glu-Asp-Gly) originally developed by the St. Petersburg Institute of Bioregulation and Gerontology in Russia. Studied for telomere lengthening, melatonin regulation, and anti-aging properties.
Same mechanism as oral Epitalon — stimulates telomerase activity in somatic cells, potentially slowing telomere shortening. Also modulates pineal gland melatonin production and may influence circadian rhythm regulation. The injectable route bypasses GI degradation, providing more consistent peptide delivery to target tissues.
Stimulates the pineal gland to increase melatonin production. Activates telomerase, an enzyme that maintains telomere length, potentially slowing cellular aging. Also reported to normalize circadian rhythms and modulate neuroendocrine function.
- Anti-aging and longevity protocols
- Telomere maintenance (investigational)
- Sleep quality improvement
- Circadian rhythm regulation
- Pineal gland support
- Anti-aging and longevity protocols
- Improved sleep quality
- Telomere length maintenance
- Cancer prevention (preliminary research)
- Circadian rhythm regulation
- Injection site reactions
- Drowsiness (melatonin-related)
- Limited human clinical data
- Long-term safety unknown
- Theoretical cancer risk from telomerase activation (unproven)
- Very limited human clinical data
- Most research from Russian institutions with limited peer review
- Long-term safety unknown
- Injection site reactions
- Theoretical concerns around telomerase activation and oncogenesis
Shares regulatory status with Epitalon. Removed from Category 2 on April 22, 2026. Scheduled for PCAC Day 2 review on July 24, 2026. Not FDA-approved for any indication.
PCAC: 2026-07-24
Removed from FDA 503A Category 2 effective April 22, 2026. Scheduled for PCAC review on July 24, 2026. Most research originates from Russian institutions; limited independent Western replication. Compounding not yet authorized — status is in regulatory gray zone pending PCAC recommendation.
PCAC: July 24, 2026
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.